Met Life Investment Management, LLC Trevi Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $16.5 Billion
- Q2 2025
A detailed history of Met Life Investment Management, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 44,656 shares of TRVI stock, worth $327,328. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,656
Previous 44,656
-0.0%
Holding current value
$327,328
Previous $280,000
12.86%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TRVI
# of Institutions
159Shares Held
91.4MCall Options Held
1.51MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$83.3 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$75.2 Million4.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$39 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$33.3 Million0.82% of portfolio
-
Siren, L.L.C. New York, NY3.94MShares$28.9 Million1.11% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $428M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...